Contact
searchSearch
HMP Global

Hepatology

Hepatology
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Robert Gish
Expert Insights
Robert Gish, MD, on Advances in Managing Hepatitis B and D
07/15/2026
Robert Gish, MD
Dr Gish discusses the recent approval of bulevirtide for the treatment of hepatitis D, and the importance of screening and monitoring patients with hepatitis B for hepatitis D to enable effective treatment.
Dr Gish discusses the recent approval of bulevirtide for the treatment of hepatitis D, and the importance of screening and monitoring patients with hepatitis B for hepatitis D to enable effective treatment.
Dr Gish discusses the recent...
07/15/2026
Gastroenterology
Manal Abdelmalek
How I Treat
How I Treat MASLD/MASH: Manal Abdelmalek, MD
07/13/2026
Manal Abdelmalek, MD
Dr Abdelmalek reviews her approach to screening, diagnosis, treatment, and monitoring of metabolic dysfunction-associated steatotic liver disease.
Dr Abdelmalek reviews her approach to screening, diagnosis, treatment, and monitoring of metabolic dysfunction-associated steatotic liver disease.
Dr Abdelmalek reviews her...
07/13/2026
Gastroenterology
Zobair Younossi
Expert Insights
Zobair Younossi, MD, on Global Consensus Recommendations for MASLD/MASH
07/02/2026
Zobair Younossi, MD
Dr Younossi reviews the recent update to global consensus recommendations for diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), including...
Dr Younossi reviews the recent update to global consensus recommendations for diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), including...
Dr Younossi reviews the recent...
07/02/2026
Gastroenterology
Robert Fontana
Expert Insights
Robert Fontana, MD, on Collaborative Care for MASLD and MASH
06/01/2026
Robert Fontana, MD
Dr Fontana recaps his presentation at Digestive Disease Week 2026 on advances in diagnosis and treatment for patients with MASLD and MASH, and the importance of collaboration among specialties as the numbers of patients with these conditions...
Dr Fontana recaps his presentation at Digestive Disease Week 2026 on advances in diagnosis and treatment for patients with MASLD and MASH, and the importance of collaboration among specialties as the numbers of patients with these conditions...
Dr Fontana recaps his...
06/01/2026
Gastroenterology
Zobair Younossi
Expert Insights
How I Treat MASLD/MASH
05/11/2026
Zobair Younossi, MD
Dr Younossi reviews his approach to managing MASLD and MASH, from screening to treatment to monitoring, and how working with a multidisciplinary team provides for better outcomes.
Dr Younossi reviews his approach to managing MASLD and MASH, from screening to treatment to monitoring, and how working with a multidisciplinary team provides for better outcomes.
Dr Younossi reviews his approach...
05/11/2026
Gastroenterology
Zobair Younossi
How I Treat MASLD/MASH
The advent of noninvasive testing methods for liver steatosis and the approval of 2 drugs to treat MASLD and MASH has positioned clinicians in primary care and internal medicine to screen...
Expert Roundtable
Advances in the Pipeline for MASLD/MASH
04/17/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In the final installment of the expert roundtable on MASLD/MASH, Drs Afdhal, Bansal, and Younossi discuss the most promising new candidate drugs in development for treatment, including some that may reverse fibrosis.
In the final installment of the expert roundtable on MASLD/MASH, Drs Afdhal, Bansal, and Younossi discuss the most promising new candidate drugs in development for treatment, including some that may reverse fibrosis.
In the final installment of the...
04/17/2026
Gastroenterology
Expert Roundtable
Monitoring Patients With MASLD/MASH
04/17/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
Our expert roundtable on MASLD/MASH reviews how to monitor patients on treatment for MASLD/MASH, including the use of PEth tests to detect alcohol consumption that may be reducing efficacy of medical therapies.
Our expert roundtable on MASLD/MASH reviews how to monitor patients on treatment for MASLD/MASH, including the use of PEth tests to detect alcohol consumption that may be reducing efficacy of medical therapies.
Our expert roundtable on...
04/17/2026
Gastroenterology
Expert Roundtable
GLP-1s, Resmetirom, Dual Therapy and More: Roundtable Continued
03/30/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
Continuing their discussion on treatment for MASLD/MASH, the expert roundtable members delve into treatment of early-stage cirrhosis and the utility of bariatric surgery for a subset of patients with these liver diseases.
Continuing their discussion on treatment for MASLD/MASH, the expert roundtable members delve into treatment of early-stage cirrhosis and the utility of bariatric surgery for a subset of patients with these liver diseases.
Continuing their discussion on...
03/30/2026
Gastroenterology
Expert Roundtable
Approved Medications for MASLD/MASH
03/30/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In Part 5 of this roundtable discussion, Drs Afdhal, Bansal, and Younossi review the approved medications resmetirom and GLP-1 receptor agonists for MASLD/MASH, including how they work, selecting patients best suited for each, using dual...
In Part 5 of this roundtable discussion, Drs Afdhal, Bansal, and Younossi review the approved medications resmetirom and GLP-1 receptor agonists for MASLD/MASH, including how they work, selecting patients best suited for each, using dual...
In Part 5 of this roundtable...
03/30/2026
Gastroenterology

News

Research Highlights
GLP-1 RAs Linked to Lower Risk of Hepatic Complications in MASLD and T2D
06/11/2026
Jessica Garlewicz
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found...
06/11/2026
Gastroenterology
Research Insights
IBS-C Microbiome Signatures Offer Insights Into Parkinson’s-Related Constipation
06/09/2026
Rebecca Mashaw
New research highlights important similarities and differences between IBS-C and Parkinson’s disease–associated constipation
New research highlights important similarities and differences between IBS-C and Parkinson’s disease–associated constipation
New research highlights...
06/09/2026
Gastroenterology
Research Review
Colonoscopy Associated With Lower Colorectal Cancer Risk in Adults Aged 40–49 Years
06/03/2026
Jessica Garlewicz
Investigators observed a lower cumulative incidence of CRC among individuals who underwent colonoscopy across both age groups studied.
Investigators observed a lower cumulative incidence of CRC among individuals who underwent colonoscopy across both age groups studied.
Investigators observed a lower...
06/03/2026
Gastroenterology
Research Insights
Early-Onset Colorectal Cancer Survivors Report Persistent Sexual Health Challenges
05/27/2026
Rebecca Mashaw
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
A new study adds to growing...
05/27/2026
Gastroenterology
Research Review
Synchronous Colon Cancer Not Associated With Worse Survival in Stage I–III Disease
05/27/2026
Jessica Garlewicz
The findings provide reassurance regarding prognosis in patients presenting with multiple primary tumors.
The findings provide reassurance regarding prognosis in patients presenting with multiple primary tumors.
The findings provide reassurance...
05/27/2026
Gastroenterology
Research Review
High Rehospitalization and Mortality Rates Persist After ICI-Associated Colitis
05/06/2026
Jessica Garlewicz
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained...
05/06/2026
Gastroenterology
Research Highlights
MAPI Offers New Biomarker in Screening for MetALD and ALD
04/23/2026
Jessica Garlewicz
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index...
04/23/2026
Gastroenterology
News
Lifetime Alcohol Intake Linked to Colorectal Cancer Risk
02/11/2026
Jessica Garlewicz
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key...
02/11/2026
Gastroenterology
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Emerging Therapies
EC Plus FOLFIRI Improves Response Rates in First-Line BRAF V600E–Mutant Metastatic Colorectal Cancer
01/14/2026
Jessica Garlewicz
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating...
01/14/2026
Gastroenterology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use